Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.